Porownywarka

GHK-Cu vs TB-500 side-by-side

Zestaw do czterech peptydów według statusu dowodów, mechanizmów, dawkowania z badań, skutków ubocznych i referencji.

Wybrane (2/4)

GHK-CuTB-500

Udostępnij porównanie peptydów

Wlasciwosc	GHK-Cu	TB-500
Kategoria	Skóra i włosy	Regeneracja
Znany tez jako	Copper Peptide, Glycyl-L-histidyl-L-lysine copper	Thymosin Beta-4 fragment (LKKTETQ), Thymosin Beta-4, Fragment
Zatwierdzony przez FDA	Nie	Nie
Status kliniczny	Used in cosmetic products with limited human topical-skincare evidence; the source also notes injectable compounding restrictions and a pending reclassification process. Pre Przedkliniczne I Faza I II Faza II III Faza III IV Faza IV FDA Zatwierdzone przez FDA	Preclinical - No human clinical trials. FDA Category 2 (pending reclassification to Category 1 per April 15, 2026 HHS announcement; remains Category 2 under current law until formal FDA rule; PCAC review July 23-24, 2026) Pre Przedkliniczne I Faza I II Faza II III Faza III IV Faza IV FDA Zatwierdzone przez FDA
Czego oczekiwac	Skin rejuvenation, wound healing, hair growth, anti-aging	Muscle recovery, wound healing, injury rehabilitation
Jak dziala	GHK-Cu is described as the copper(II) complex of the GHK tripeptide. The source connects its activity to copper binding and possible cellular copper delivery, but also emphasizes effects that go beyond a simple carrier model. Reported laboratory observations include shifts in gene expression, increased fibroblast production of extracellular-matrix components, keratinocyte support, vascular-related activity, and antioxidant or anti-inflammatory signals. The precise mechanism is still not fully defined.	TB-500 is presented as a synthetic peptide based on the thymosin beta-4 active region. The supplied source identifies LKKTETQ, residues 17 to 23, as the short sequence commonly reproduced in TB-500 products and ties that region to G-actin binding. Through this actin-related pathway, thymosin beta-4 research connects cytoskeletal remodeling with cell migration into wound areas. The source also reports anti-inflammatory and pro-angiogenic activity in lab models. The main uncertainty is translational: evidence from full-length thymosin beta-4 does not prove that a 7-amino-acid fragment will reproduce the parent molecule's full biological profile.
Typowe dawkowanie	1-2 mg daily injection or 0.05% topical · Once daily · Subcutaneous injection or topical application	2-2.5 mg twice weekly (loading), then 2.5 mg once weekly (maintenance) · 2x weekly for 4-6 weeks, then 1x weekly
Dawkowanie z badań	1-2 mg for injectable protocols · Varies by application · Subcutaneous injection or topical application	2-2.5 mg twice weekly · 4-6 weeks loading, then maintenance · Subcutaneous or intramuscular injection
Typowy czas trwania	Varies by application	4-6 weeks loading, then maintenance
Podanie	Subcutaneous injection or topical application	Subcutaneous or intramuscular injection
Timing	Evening for skin or recovery contexts With or without food	Morning or evening With or without food
Poziom dowodów	Badania kliniczne	Przedkliniczne
Mozliwe skutki uboczne	Generally well tolerated (Reported as a general tolerability statement in the source.) Mild topical irritation, redness, or tingling (Associated with topical use.) Injection-site reactions (Associated with injectable use.) +4 więcej Possible histamine release (Source advises caution for MCAS or histamine sensitivity.) Copper toxicity risk with excessive use (Risk described for excessive exposure.) Wilson's disease contraindication (Source lists Wilson's disease as contraindicated.) Caution with active cancer (Source flags an angiogenesis-related concern.)	Generally well-tolerated in preclinical studies (Preclinical observation; long-term human safety data are limited.) Injection site reactions Headache +7 więcej Fatigue Nausea May trigger histamine release (Source advises caution for MCAS or histamine sensitivity.) Theoretical risk of facilitating tumor cell migration (Source notes thymosin beta-4 is upregulated in metastatic cancers.) Contraindicated with active cancer or cancer history (Source-supported contraindication note.) Limited long-term safety data WADA prohibited at all times (Listed in the source as prohibited on the 2025 WADA list.)
Podsumowanie researchu	The source describes a mixed evidence base. Cell and animal work is reported for wound repair, collagen deposition, fibroblast activity, elastin and growth-factor production, keratinocyte protection, and lung-injury models. Human data are described as small topical cosmetic studies, including facial-cream and eye-cream studies with 71 and 41 participants that reported changes in skin density, thickness, and wrinkle appearance. These data are encouraging for topical skin endpoints but do not establish injected or systemic benefits.	The supplied research summary places TB-500 mainly in a preclinical evidence category and says most of the stronger evidence concerns full-length thymosin beta-4 rather than the TB-500 fragment. It reports animal findings in wound, scar, tendon, skin, and cardiac injury models. For human data, the source discusses RegeneRx programs using thymosin beta-4 forms: RGN-259 eye drops in a placebo-controlled Phase 3 neurotrophic keratopathy study, where corneal healing was reported in 6 of 10 treated patients versus 1 of 8 on placebo, and RGN-352 injection, which reached Phase 2 in a cardiac program before a manufacturing hold. These programs are not presented as human efficacy trials of the 7-amino-acid TB-500 fragment. For TB-500 as a fragment, the source states there are no completed, published human efficacy trials for muscle or tendon repair and mentions a recently listed cardiovascular biomarker study as early-stage.
Referencje	PubMed PubMed +1 więcej PubMed	Źródło Źródło +2 więcej Źródło Źródło
Pełny profil	Zobacz szczegóły	Zobacz szczegóły

Zapisz to porównanie

Trzymaj ten zestaw researchowy pod reka na darmowym koncie PeptiGuide.

Zapisz porównanie - darmowe konto

Trackuj swoja ścieżkę peptydówa

Zamien research w prywatny log protokołu, gdy będziesz gotowy.

Trackuj ścieżkę peptydówa

Wyłącznie edukacyjnie. Te informacje są agregowane z publicznych badań i raportów społeczności. To nie jest poradą medyczną, a informacje o dawkowaniu są opisowe, nie rekomendacyjne. Zawsze konsultuj się z wykwalifikowanym specjalistą ochrony zdrowia.

Wlasciwosc

GHK-Cu

TB-500

Kategoria

Skóra i włosy

Regeneracja

Znany tez jako

Copper Peptide, Glycyl-L-histidyl-L-lysine copper

Thymosin Beta-4 fragment (LKKTETQ), Thymosin Beta-4, Fragment

Zatwierdzony przez FDA

Nie

Status kliniczny

Used in cosmetic products with limited human topical-skincare evidence; the source also notes injectable compounding restrictions and a pending reclassification process.

Pre
Przedkliniczne
I
Faza I
II
Faza II
III
Faza III
IV
Faza IV
FDA
Zatwierdzone przez FDA

Preclinical - No human clinical trials. FDA Category 2 (pending reclassification to Category 1 per April 15, 2026 HHS announcement; remains Category 2 under current law until formal FDA rule; PCAC review July 23-24, 2026)

Pre
Przedkliniczne
I
Faza I
II
Faza II
III
Faza III
IV
Faza IV
FDA
Zatwierdzone przez FDA

Czego oczekiwac

Skin rejuvenation, wound healing, hair growth, anti-aging

Muscle recovery, wound healing, injury rehabilitation

Jak dziala

GHK-Cu is described as the copper(II) complex of the GHK tripeptide. The source connects its activity to copper binding and possible cellular copper delivery, but also emphasizes effects that go beyond a simple carrier model. Reported laboratory observations include shifts in gene expression, increased fibroblast production of extracellular-matrix components, keratinocyte support, vascular-related activity, and antioxidant or anti-inflammatory signals. The precise mechanism is still not fully defined.

TB-500 is presented as a synthetic peptide based on the thymosin beta-4 active region. The supplied source identifies LKKTETQ, residues 17 to 23, as the short sequence commonly reproduced in TB-500 products and ties that region to G-actin binding. Through this actin-related pathway, thymosin beta-4 research connects cytoskeletal remodeling with cell migration into wound areas. The source also reports anti-inflammatory and pro-angiogenic activity in lab models. The main uncertainty is translational: evidence from full-length thymosin beta-4 does not prove that a 7-amino-acid fragment will reproduce the parent molecule's full biological profile.

Typowe dawkowanie

1-2 mg daily injection or 0.05% topical · Once daily · Subcutaneous injection or topical application

2-2.5 mg twice weekly (loading), then 2.5 mg once weekly (maintenance) · 2x weekly for 4-6 weeks, then 1x weekly

Dawkowanie z badań

1-2 mg for injectable protocols · Varies by application · Subcutaneous injection or topical application

2-2.5 mg twice weekly · 4-6 weeks loading, then maintenance · Subcutaneous or intramuscular injection

Typowy czas trwania

Varies by application

4-6 weeks loading, then maintenance

Podanie

Subcutaneous injection or topical application

Subcutaneous or intramuscular injection

Timing

Evening for skin or recovery contexts

With or without food

Morning or evening

With or without food

Poziom dowodów

Badania kliniczne

Przedkliniczne

Mozliwe skutki uboczne

Generally well tolerated (Reported as a general tolerability statement in the source.)
Mild topical irritation, redness, or tingling (Associated with topical use.)
Injection-site reactions (Associated with injectable use.)

+4 więcej

Possible histamine release (Source advises caution for MCAS or histamine sensitivity.)
Copper toxicity risk with excessive use (Risk described for excessive exposure.)
Wilson's disease contraindication (Source lists Wilson's disease as contraindicated.)
Caution with active cancer (Source flags an angiogenesis-related concern.)

Generally well-tolerated in preclinical studies (Preclinical observation; long-term human safety data are limited.)
Injection site reactions
Headache

+7 więcej

Fatigue
Nausea
May trigger histamine release (Source advises caution for MCAS or histamine sensitivity.)
Theoretical risk of facilitating tumor cell migration (Source notes thymosin beta-4 is upregulated in metastatic cancers.)
Contraindicated with active cancer or cancer history (Source-supported contraindication note.)
Limited long-term safety data
WADA prohibited at all times (Listed in the source as prohibited on the 2025 WADA list.)

Podsumowanie researchu

The source describes a mixed evidence base. Cell and animal work is reported for wound repair, collagen deposition, fibroblast activity, elastin and growth-factor production, keratinocyte protection, and lung-injury models. Human data are described as small topical cosmetic studies, including facial-cream and eye-cream studies with 71 and 41 participants that reported changes in skin density, thickness, and wrinkle appearance. These data are encouraging for topical skin endpoints but do not establish injected or systemic benefits.

The supplied research summary places TB-500 mainly in a preclinical evidence category and says most of the stronger evidence concerns full-length thymosin beta-4 rather than the TB-500 fragment. It reports animal findings in wound, scar, tendon, skin, and cardiac injury models. For human data, the source discusses RegeneRx programs using thymosin beta-4 forms: RGN-259 eye drops in a placebo-controlled Phase 3 neurotrophic keratopathy study, where corneal healing was reported in 6 of 10 treated patients versus 1 of 8 on placebo, and RGN-352 injection, which reached Phase 2 in a cardiac program before a manufacturing hold. These programs are not presented as human efficacy trials of the 7-amino-acid TB-500 fragment. For TB-500 as a fragment, the source states there are no completed, published human efficacy trials for muscle or tendon repair and mentions a recently listed cardiovascular biomarker study as early-stage.

Referencje

+1 więcej

+2 więcej

Pełny profil